BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This is a dose escalation and dose expansion study to compare how well BGB-43395, a
cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with
either fulvestrant or letrozole in participants with hormone receptor positive (HR+) and
human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid
tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.